Latest News - Pfizer
Top Corporates Hub
Pfizer
2 Dirt Cheap Healthcare Stocks to Buy in July
07.07.2026 12:30
Healthcare has become Wall Street’s bargain bin in 2026, and value hunters are starting to pay attention. Drug pricing reform, patent cliffs and post-COVID-19 hangovers have crushed multiples across Big Pharma, but the wreckage has created opportunities in two cash-generative franchises trading at single-digit forward earnings multiples. Heading into July, Novo Nordisk and Pfizer stand ... 2 Dirt Cheap Healthcare Stocks to Buy in July
Can Alnylam's Drug Pipeline Fuel Its Long-Term Revenue Growth?
06.07.2026 15:55
ALNY's advancing pipeline and partnered programs can expand future revenue sources alongside its growing portfolio of approved therapies.
Pfizer (PFE) Wins FDA Approval For IBRANCE In HER2 Positive Breast Cancer
06.07.2026 14:10
Pfizer's IBRANCE has received new FDA approval as the first CDK4/6 inhibitor maintenance therapy for HR+, HER2+ metastatic breast cancer after induction treatment. The approval covers use of IBRANCE in combination with trastuzumab and endocrine therapy for patients with this subtype of breast cancer. The decision is based on results from the Phase 3 PATINA trial. For investors watching Pfizer (NYSE:PFE), this approval adds a fresh clinical milestone to a stock that has faced pressure in...
Cantor Fitzgerald Reiterates Neutral on Pfizer, Maintains $27 Price Target
06.07.2026 09:23
Cantor Fitzgerald analyst Carter Gould reiterates Pfizer (NYSE:PFE) with a Neutral and maintains $27 price target.
This M&T Bank Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
06.07.2026 07:19
Top analysts changed outlook on top names. Visit analyst ratings page for complete view. See opinions on HBAN, PFE, DAL, MTB, BRO stocks.
HSBC Downgrades Pfizer to Hold, Lowers Price Target to $28
06.07.2026 05:53
HSBC analyst Rajesh Kumar downgrades Pfizer (NYSE:PFE) from Buy to Hold and lowers the price target from $32 to $28.
Trump Financial Disclosure Shows 21,000 Trades in 2025
02.07.2026 17:58
(Bloomberg) -- President Donald Trump made more than 21,000 securities trades in his first year back in office, often in intense bursts tied to market events he created.Most Read from BloombergExxon to Change Name for First Time in Decades After RedomicileMeta Is Planning a Cloud Business to Sell AI Computing PowerGermany Rejects Trump’s Demands for NATO Loyalty to WashingtonRussia Indicates Ukraine Fired Long-Range Ballistic MissileKrafton Agrees to Pay ‘Subnautica 2’ Bonuses as Developer’s CEO
Ascendis Pharma: Behind The Stock Surge
02.07.2026 09:44
Ascendis Pharma stock surged on Yorvipathâs blockbuster launch and Yuviwel FDA approval. Read the latest analysis on ASND stock here.
WHO Director-General Ghebreyesus Says He Considers The Cruise Ship-Linked Hantavirus Outbreak To Be Over
02.07.2026 09:18
https://t.co/sFqLF8qeSI
Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage
01.07.2026 12:13
Medicare's new GLP-1 coverage could expand access to weight-loss drugs, making ETFs a diversified way to tap growth across the obesity treatment market.
Doctor-turned-dealmaker reveals his M&A playbook
01.07.2026 09:05
Dr. David Hung is pulling multiple financial levers to put Nuvation Bio on strong footing as it advances its oncology drugs.
Is Pfizer (PFE) Stock Undervalued Despite Mixed Oncology Progress?
01.07.2026 04:30
Pfizer stock is trading in a range where recent returns have been weak over three years, yet the broader valuation checks still lean cheap and suggest the current share price may not fully reflect the company’s fundamentals. Over the past 3 years, Pfizer has delivered a total return that is down about 21%, which shows how much sentiment has cooled since its pandemic peak. The push into oncology and obesity treatments, including recent IBRANCE progress and weight loss drug development, can...
This 7% Yielding Healthcare Powerhouse Belongs in Retirees’ Portfolios
30.06.2026 13:50
Few large-cap dividends generate as much skepticism as Pfizer (NYSE:PFE). The stock trades at $24.37, and the COVID franchise erosion has been brutal, with Comirnaty down 59% and Paxlovid down 63% in Q1 2026. Yet the dividend keeps coming. I want to know if that 7.27% yield is a gift or a warning. The Dividend ... This 7% Yielding Healthcare Powerhouse Belongs in Retirees’ Portfolios
Why Pfizer Could Prove to Be an Underrated GLP-1 Stock
30.06.2026 13:20
It could prove to be a case of better later than never for the healthcare giant.
U.S. House Committee Sends Letters To Pfizer, Eli Lilly & Bristol Myers Squibb Probing China Drug Trials
30.06.2026 09:50
- Reuters
Nike Analyst Turns Bearish As Recovery Takes Longer Than Expected
26.06.2026 10:53
KeyBanc downgraded Nike, citing slower-than-expected progress in its turnaround strategy and mounting competition from rival brands.
Beam Therapeutics: A Better Entry Point Is Likely Coming (Rating Downgrade)
26.06.2026 08:40
Beam Therapeutics could have a moat around its business due to Risto-cel showing competitive efficacy. See why BEAM stock is downgraded to a hold.
2026 Mid-Year Outlook: Big Market Risks, AI And Memory Mania Concerns, And My Top Bargain Stock Picks
26.06.2026 04:58
Broad market bearishness prompts defensive buys in oversold defense stocks, high-yield Pfizer, and cash reserves. Read more here.
Ozempic Sat Unused For Decades Because Invention Is Not Enough
26.06.2026 00:45
Led by Ozempic and Wegovy, glucagon-like peptides (GLP-1s) have become a global phenomenon, with one in eight US adults currently taking one.